Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chloroquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.98 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.98 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.98 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.84 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.98 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | PRNP | P04156 | 1/20 | 0.98 |
| ▸ | APP | P05067 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroquine SCHEMBL9862220 | 1.00 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL30162948 | 1.00 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL30298851 | 1.00 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL29363614 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| (R)-Chloroquine SCHEMBL134500 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| (R)-Chloroquine SCHEMBL29429108 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8934 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8474661 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8933 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL23152713 | 0.98 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1038 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111328811-B | Low-concentration alcohol sterilization disinfectant and application thereof | 广州康健医学科技有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-111675652-A | Chloroquine glycyrrhetate or hydroxychloroquine glycyrrhetate, and preparation method and application thereof | 深圳市萱嘉生物科技有限公司 | 2020-09-18 | — | — | CN | claimed |
| CN-111606966-A | Chloroquine glycyrrhetinate or hydroxychloroquine glycyrrhetinate, and preparation method and application thereof | 深圳市萱嘉生物科技有限公司 | 2020-09-01 | — | — | CN | claimed |
| CN-111436187-A | Blend of a bio-stimulant based on folate impurity 10 and an agrochemical of interest that produces a quantitative, qualitative and time-related result enhancement as observed in crops of plants of interest | UPL有限责任公司 | 2020-07-21 | — | — | CN | claimed |
| CN-111419787-A | Chloroquine spray and preparation method thereof | 广州康健医学科技有限公司 | 2020-07-17 | — | — | CN | claimed |
| CN-111328811-A | Low-concentration alcohol sterilization disinfectant and application thereof | 广州康健医学科技有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-111053707-B | Liquid film protective agent for disinfection protection and preparation method and application thereof | 广州康健医学科技有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-111297800-A | Ion exchange fiber chloroquine suspension and preparation method thereof | 广州康健医学科技有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-111053707-A | Liquid film protective agent for disinfection protection and preparation method and application thereof | 广州康健医学科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-104971062-B | Irinotecan class medicine and chloroquine class drug regimen and its altogether load liposome and preparation | 浙江大学 | 2017-11-21 | — | — | CN | claimed |
| EP-1863927-A2 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INFLAMMATORY DISORDERS | Ares Trading S.A. (CH) | 2007-12-12 | — | — | EP | claimed |
| WO-2006097463-A2 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INFLAMMATORY DISORDERS | ARES TRADING S.A. (CH) | 2006-09-21 | — | — | WO | claimed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| US-5021426-A | Mixture with chloroquine, hydroxychloroquine, amodiaquine, mefloquine or salts thereof | MERCK & CO., INC. (US) | 1991-06-04 | — | — | US | claimed |
| US-4525350-A | Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1 | THE NEW ENGLAND INSTITUTE, INC. (US) | 1985-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | CHRM2 4176/4885CHRM4 3648/4885CHRM5 3656/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | CHRM2 1772/4885CHRM4 2179/4885CHRM5 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.